International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 4 , Pages 1023-1032 , 15 March 2009

Predictive Factors for Acute and Late Urinary Toxicity After Permanent Prostate Brachytherapy: Long-Term Outcome in 712 Consecutive Patients

  • Mira Keyes, M.D.

      Affiliations

    • Vancouver Cancer Center, Vancouver, BC, Canada
    • Corresponding Author InformationReprint requests to: Mira Keyes, M.D., F.R.C.P.C., Department of Radiation Oncology, Department of Surgery, University of British Columbia, Provincial Prostate Brachytherapy Program, BC Cancer Agency, 600 W. 10th Ave., Vancouver, BC V5Z 4E6 Canada. Tel: (604) 877-6000, ext. 2660; Fax: (604) 877-0505
    • ,
  • Stacy Miller, M.D.

      Affiliations

    • Vancouver Cancer Center, Vancouver, BC, Canada
    • ,
  • Veronika Moravan, M.Sc.

      Affiliations

    • Population and Preventive Oncology, Vancouver Island Cancer Centre, Vancouver, BC, Canada
    • ,
  • Tom Pickles, M.D.

      Affiliations

    • Vancouver Cancer Center, Vancouver, BC, Canada
    • ,
  • Michael McKenzie, M.D.

      Affiliations

    • Vancouver Cancer Center, Vancouver, BC, Canada
    • ,
  • Howard Pai, M.D.

      Affiliations

    • Population and Preventive Oncology, Vancouver Island Cancer Centre, Vancouver, BC, Canada
    • ,
  • Mitchell Liu, M.D.C.M.

      Affiliations

    • Fraser Valley Cancer Centre for Southern Interior Provincial Prostate Brachytherapy Program, Vancouver, BC, Canada
    • ,
  • Winkle Kwan, M.D.

      Affiliations

    • Fraser Valley Cancer Centre for Southern Interior Provincial Prostate Brachytherapy Program, Vancouver, BC, Canada
    • ,
  • Alexander Agranovich, M.D.

      Affiliations

    • Fraser Valley Cancer Centre for Southern Interior Provincial Prostate Brachytherapy Program, Vancouver, BC, Canada
    • ,
  • Ingrid Spadinger, Ph.D.

      Affiliations

    • Vancouver Cancer Center, Vancouver, BC, Canada
    • ,
  • Vincent Lapointe, M.Sc.

      Affiliations

    • Vancouver Cancer Center, Vancouver, BC, Canada
    • ,
  • Ross Halperin, M.D.

      Affiliations

    • British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • W. James Morris, M.D.

      Affiliations

    • Vancouver Cancer Center, Vancouver, BC, Canada

Received 14 March 2008 ,Revised 14 May 2008 ,Accepted 15 May 2008.

References 

  1. Grimm PD, Blasko JC, Sylvester JE, et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40
  2. Potters L, Morgenstern C, Calugaru E, et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005;173:1562–1566
  3. Zelefsky MJ, Yamada Y, Cohen GN, et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:65–70
  4. Gelblum DY, Potters L, Ashley R, et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999;45:59–67
  5. Keyes M, Schellenberg D, Moravan V, et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?. Int J Radiat Oncol Biol Phys. 2006;64:825–834
  6. Stone NN, Stock RG. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology. 2007;69:338–342
  7. Niehaus A, Merrick GS, Butler WM, et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;64:136–143
  8. Crook J, Fleshner N, Roberts C, et al. Long-term urinary sequelae following 125Iodine prostate brachytherapy. J Urol. 2008;179:141–146
  9. Brown D, Colonias A, Miller R, et al. Urinary morbidity with a modified peripheral loading technique of transperineal 125I prostate implantation. Int J Radiat Oncol Biol Phys. 2000;47:353–360
  10. Merrick GS, Butler WM, Lief JH, et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;47:121–128
  11. Henderson A, Ismail AK, Cunningham M, et al. Toxicity and early biochemical outcomes from 125Iodine prostate brachytherapy in the UK: A prospective study. Clin Oncol (R Coll Radiol). 2004;16:95–104
  12. Kelly K, Swindell R, Routledge J, et al. Prediction of urinary symptoms after 125iodine prostate brachytherapy. Clin Oncol (R Coll Radiol). 2006;18:326–332
  13. Morris WJ, Keyes M, McKenzie MR, et al. LDR brachytherapy for prostate cancer: Analysis of outcomes for the first 1006 patients treated at the British Columbia Cancer Agency. (BCCA [Abstract].) Brachytherapy. 2008;7:Abstract 20
  14. Morris J, Keyes M, McKenzie M, et al. The five-year relapse-free and overall survival following permanent 125 iodine prostate brachytherapy. Radiother Oncol. 2006;80:S42
  15. Blasko JC, Mate T, Sylvester JE, et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol. 2002;12:81–94
  16. Barry MJ, Fowler FJ, O'Leary MP, et al. for the Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148:1549–1557discussion 1564
  17. Lawton CA, Won M, Pilepich MV, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 1991;21:935–939
  18. Neil M, Studer G, Lee LN, et al. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry. Brachytherapy. 2007;6:173–179
  19. Merrick GS, Butler WM, Wallner KE, et al. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy. Urology. 2006;68:116–120
  20. Kucway R, Vicini F, Huang R, et al. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol. 2002;167:2443–2447
  21. Allen ZA, Merrick GS, Butler WM, et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys. 2005;62:981–987
  22. Hinerman-Mulroy A, Merrick GS, Butler WM, et al. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2004;59:1367–1382
  23. Thomas C, Keyes M, Liu M, et al. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms prior to permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2008;72:447–455
  24. Miller S, Keyes M, Moravan V, et al. Late urinary symptom flare following prostate brachytherapy. [Abstract] Radiother Oncol. 2006;80:S39;Abstract 133
  25. Salem N, Simonian-Sauve M, Rosello R, et al. Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localised prostate cancer: A phase 2 study. Radiother Oncol. 2003;66:159–165
  26. Zelefsky MJ, Hollister T, Raben A, et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;47:1261–1266
  27. Stock RG, Stone NN, Dahlal M, et al. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Brachytherapy. 2002;1:83–89
  28. Van Gellekom MP, Moerland MA, Van Vulpen M, et al. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. Int J Radiat Oncol Biol Phys. 2005;63:772–780
  29. Henderson A, Bott SR, Sooriakumaran P, et al. Urinary morbidity after 125I brachytherapy of the prostate. BJU Int. 2004;93:890
  30. Merrick GS, Butler WM, Galbreath RW, et al. Relationship between the transition zone index of the prostate gland and urinary morbidity after brachytherapy. Urology. 2001;57:524–529
  31. Zelefsky MJ, Yamada Y, Marion C, et al. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:956–963
  32. Talcott JA, Clark JA, Stark PC, et al. Long-term treatment related complications of brachytherapy for early prostate cancer: A survey of patients previously treated. J Urol. 2001;166:494–499
  33. Merrick GS, Butler WM, Wallner KE, et al. Variability of prostate brachytherapy pre-implant dosimetry: A multi-institutional analysis. Brachytherapy. 2005;4:241–251
  34. Macdonald AG, Keyes M, Kruk A, et al. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important?. Int J Radiat Oncol Biol Phys. 2005;63:155–163

 Presented at the ESTRO Leipzig, September 2006 and ABS Chicago, May 2007.

 Conflict of interest: none.

PII: S0360-3016(08)00847-X

doi: 10.1016/j.ijrobp.2008.05.022

International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 4 , Pages 1023-1032 , 15 March 2009

Article Tools

* Image Usage & Resolution